Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season (Revised)

By Zacks Investment ResearchStock MarketsJul 09, 2021 12:41AM ET
www.investing.com/analysis/3-big-drugmakers-to-buy-ahead-of-the-q2-earnings-season-revised-200590578
3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season (Revised)
By Zacks Investment Research   |  Jul 09, 2021 12:41AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
PFE
-0.55%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ALXN
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AZN
+0.47%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ABBV
-0.43%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BAYRY
+0.85%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

The big drug companies are set for the second-quarter earnings season, which begins later this month. Though the second-quarter results are likely to reflect continued negative impact from the pandemic, trends are expected to be better as economies have re-opened and vaccinations continue in full swing.

Importantly, a number of big drugmakers, including Pfizer (NYSE:PFE) and AstraZeneca (NASDAQ:AZN), have seen a surge in their sales after getting emergency approvals for their COVID-19 vaccines, a trend expected to have continued in the second quarter.

Overall, the drug/biotech industry continues to witness developments and improvements in drug research in 2021 while withstanding the impact of the pandemic remarkably well. While development updates related to COVID-19 medicines/vaccines continued have taken center stage this year as well, the sector also witnessed positive developments in other innovative pipeline areas.

Here we have highlighted three bigshot drugmakers, AstraZeneca AZN, AbbVie ABBV and Bayer (OTC:BAYRY) BAYRY, which can prove to be good additions to improve your portfolio’s health as all three have a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

A chart showing the share price movement of these companies this year so far is given below.

Zacks Investment Research
Zacks Investment Research
Image Source: Zacks Investment Research

AstraZeneca

AstraZeneca’s stock has risen 21.6% this year so far. Its earnings estimates for 2022 have gone up from $3.24 per share to $3.25 per share over the past 60 days.

Incidentally, AstraZeneca has faced quite a lot of troubles related to its COVID-19 vaccine’s use and COVID-19 drug development efforts this year.A possible link between AstraZeneca’s COVID-19 vaccine and rare blood clot events in the brain of the people who have received the shot have been found by regulatory authorities. In March, many European countries had temporarily paused vaccinations with AstraZeneca’s jab due to the blood clot controversies. Though most countries resumed vaccinations later on, some countries however restricted its use in younger people. Separately, data released last month, showed that AstraZeneca's investigational antibody cocktail for COVID-19, AZD7442 failed to prevent people who were already infected from developing symptomatic COVID-19.

Nonetheless, it has been a good first half for AstraZeneca as far as its other pipeline efforts are concerned. In January, its innovative cancer drug, Enhertu, developed in collaboration with Daiichi Sankyo, was approved for its second indication, HER2+, metastatic gastric cancer. Its blockbuster diabetes medicine, Farxiga was approved for another indication, chronic kidney disease (CKD), in April 2021. Importantly, its COVID-19 vaccine, developed in collaboration with the University of Oxford, is approved for temporary/conditional use in several countries in less than a year from when they signed the agreement to jointly develop. The vaccine increased its total sales in the first quarter of 2021.

Moreover, its newer oncology medicines such as Tagrisso, Lynparza and Imfinzi are driving the company’s sales, making up for the decline in the Respiratory & Immunology franchise.

AstraZeneca is also due to acquire rare disease drugmaker and S&P component, Alexion (NASDAQ:ALXN). With the acquisition, the company aims to develop its immunology business further. The acquisition is expected to close in the third quarter of 2021.

AbbVie

AbbVie’s stock is up 7.4% this year so far. Estimates for 2021 earnings have increased from $12.59 to $12.60 per share in the past 60 days while that for 2022 have risen from $13.96 to $14.00 over the same period

AbbVie has been successful in expanding labels of its cancer drugs, Imbruvica and Venclexta. AbbVie has built a substantial oncology franchise with Imbruvica and Venclexta, which have become key contributors to sales growth.

Its two new immunology drugs, Skyrizi and Rinvoq, are also performing beyond expectations. With many new indications coming in the next couple of years, sales of these drugs could be higher and have the potential to replace Humira when generics are launched in 2023.

It has an impressive late-stage pipeline with several early/mid-stage candidates that have blockbuster potential. AbbVie expects approval of more than a dozen new products/line extensions for major indications over the next two years, which can collectively add meaningful revenue growth in advance of the U.S. Humira loss of exclusivity in 2023.

Bayer

Bayer’s stock is up 3.6% this year so far. Estimates for Bayer’s 2021 earnings have increased from $1.74 to $1.81 per share in the past 60 days while that for 2022 have risen from $1.89 to $2.00 over the same period

Bayer’s Crop Science division is demonstrating an encouraging sales performance amid an improving market environment. Sales in Bayer’s Pharmaceuticals unit have remained steady driven by strong sales of its partnered medicines, oral anticoagulant Xarelto and eye drug Eylea. Bayer’s Consumer Health division has outperformed competition.

The company is undertaking several initiatives to strengthen its position across portfolios, including the divestiture of the Animal Health business unit and the Consumer Health brands — Coppertone and Dr. Scholl’s. Bayer also sold its 60% interest in Germany-based site services provider, Currenta. Moreover, the recent acquisition of Asklepios will strengthen Bayer’s cell and gene therapy platform. Restructuring initiatives should help the bottom line.

(We are reissuing this article to correct a mistake. The original article, issued on July 6, 2021, should no longer be relied upon.)


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN): Free Stock Analysis Report

Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report

AbbVie Inc. (NYSE:ABBV): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season (Revised)
 

Related Articles

David Moenning
Has a New Bull Arrived? By David Moenning - Jan 30, 2023 1

In last week's meandering market missive, I opined that, "the next major trend - in either direction - is likely to be driven by the outlook/expectation for the state of the...

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season (Revised)

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email